MENU

ALPMY Stock Astellas Pharma (ALPMY, $9.82) was a top winner yesterday, jumping +3.26%

A.I.dvisor
at Tickeron.com
Loading...
ALPMY - Astellas Pharma, Inc.
Tickeron

Loading...

Price: $9.82
Daily change: +$0.31 (+3.26%)
Daily volume: 1.1M
Capitalization: $17.5B
Industry: Pharmaceuticals: Major

Astellas Pharma (ALPMY, $9.82) was one of the top gainers yesterday, rising to $9.82 per share. A.I.dvisor analyzed 58 stocks in the Pharmaceuticals: Major Industry and found that of them (7) are in an Uptrend while of them (2) are in a Downtrend.

Aroon Indicator for ALPMY shows an upward move is likely

ALPMY's Aroon Indicator triggered a bullish signal on January 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 187 similar instances where the Aroon Indicator showed a similar pattern. In of the 187 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 05, 2026. You may want to consider a long position or call options on ALPMY as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALPMY just turned positive on January 08, 2026. Looking at past instances where ALPMY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPMY advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALPMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALPMY broke above its upper Bollinger Band on January 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.565) is normal, around the industry mean (9.607). P/E Ratio (33.215) is within average values for comparable stocks, (24.682). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.998). Dividend Yield (0.035) settles around the average of (0.025) among similar stocks. P/S Ratio (2.067) is also within normal values, averaging (3.957).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALPMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ALPMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ALPMY showed earnings on October 30, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
2-5-1, Nihonbashi-Honcho
Phone
+81 332443000
Employees
16243
Web
http://www.astellas.com